Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol

Current Medical Research and Opinion

Volumn 26, Issue 11, 2010, Pages 2527-2533

  Pavkov, Richard ^a   Mueller, Stefan ^a   Fiebich, Katrin ^a   Singh, Dilraj ^a   Stowasser, Frank ^a   Pignatelli, Giovanni ^a   Walter, Benoît ^a   Ziegler, Dominik ^a   Dalvi, Mukul ^a   Dederichs, Juergen ^a   Rietveld, Ilse ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Pharma BV   (Netherlands)

Author keywords

COPD; Dry powder inhaler; Indacaterol

Indexed keywords

GLYCOPYRRONIUM BROMIDE; INDACATEROL; NEW DRUG; QVA 149; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DEVICE; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRY POWDER; FEMALE; HUMAN; MALE; MECHANICAL STRESS; PEAK INSPIRATORY FLOW; POWDER INHALER;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AGED, 80 AND OVER; DRY POWDER INHALERS; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NETHERLANDS; PATIENT COMPLIANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SEVERITY OF ILLNESS INDEX;

EID: 77958141697     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.518916     Document Type: Article

References (34)

1. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005;50:1313-21
2. Ashurst I, Malton A, Prime D, et al. Latest advances in the development of dry powder inhalers. Pharm Sci Technol Today 2000;3:246-56
3. Newman SP. Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther 2004;4:23-33
4. Chrystyn H. Closer to an 'Ideal Inhaler' with the Easyhaler: an innovative dry powder inhaler. Clin Drug Invest 2006;26:175-83
5. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002;96:293-304
6. Byron PR. Drug delivery devices: issues in drug development. Proc Am Thoracic Soc 2004;1:321-8
7. Bisgaard H. Drug delivery from inhaler devices. Lung deposition, clinical effect and cost effectiveness vary. Br Med J 1996;313:895-6
8. Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir Care. 2005;50:1191-200
9. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127:335-71
10. Broeders ME, Molema J, Hop WC, et al. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. J Aerosol Med 2003;16:131-41
11. Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003;16:249-54
12. Roche N, Huchon GJ. Rationale for the choice of an aerosol delivery system. J Aerosol Med 2000;13:393-404
13. Girodet PO, Raherison C, Abouelfath A, et al. Real-life use of inhaler devices for chronic obstructive pulmonary disease in primary care. Therapie 2003;58: 499-504
14. National Asthma Council Australia. Inhaler technique in adults with asthma or COPD. National Asthma Council Australia, 2008
15. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008;102:593-604
16. 2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD. Curr Med Res Opin 2007;23: 2405-13
17. Mueller S, Haeberlin B, Edge S. Comparison of performance characteristics for Foradil Aerolizer® and Foradil Concept1 (a new single dose dry powder inhaler) at different test flow rates. Resp Drug Deliv 2008;3:675-8
18. Mueller S, Haeberlin B, Edge S. Comparison of device robustness and cleaning characteristics for Foradil Concept1 (a new single dose dry powder inhaler) and Foradil Aerolizer®. Resp Drug Deliv 2008;3:679-82
19. Pavkov R, Singh D, Reitveld I. Concept1 (a new single dose dry powder inhaler) peak inspiratory flow rate study with COPD patients. Resp Drug Deliv 2008;3:683-6
20. Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005;14:775-83
21. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008;102:1033-44
22. Bauwens O, Ninane V, Van de Maele B, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009;25:463-70
23. Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008;75:18-25
24. Terzano C. Dry powder inhalers and the risk of error. Respiration 2008; 75:14-15
25. Pavkov R, Singh D, Rietveld I. Concept1 (a new single dose dry powder inhaler) Peak inspiratory flow rate study with COPD patients. Poster presented at Respiratory Drug Delivery 2008, May 11-15, Arizona, USA
26. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med 1993;6:99-110
27. European Pharmacopoeia 6th Edition. Preparations for inhalation. pp. 739-42
28. European Medicines Agency (EMEA), Committee For Medicinal Products For Human Use (CHMP). Guideline on the pharmaceutical quality of inhalation and nasal products, 2006
29. Collins S. Determination of emitted dose from dry powder inhalers II; comparison of the pharmacopoeial forum apparatus and the funnel apparatus. Drug Delivery to the Lungs IX. 1998:60-3
30. United States Pharmacopeial Convention. Chapter 601. Aerosols, metered-dose inhalers, and dry powder inhalers. In: USP30-NF25. Rockville, MD: USP, 2009
31. Clark AR. Effect of powder inhaler resistance upon inspiratory profiles in health and disease. In: Dalby RN, Byron PR, Farr SJ, eds. Respiratory Drug Delivery IV. Buffalo Grove: Interpharm Press, 1994:117-24
32. Srichana T, Martin GP, Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci 1998;7:73-80 (Pubitemid 29056229)
33. Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008; 31:78-83
34. Van Der Palen J, Eijsvogel MM, Kuipers BF, et al. Comparison of the Diskus inhaler and the Handihaler regarding preference and ease of use. J Aerosol Med 2007;20:38-44